# Lipidomic Signature of Patients with Familial Hypercholesterolemia Carrying Pathogenic Variants Unveils a Cue of Increased Cardiovascular Risk

## TL;DR

This study identifies unique lipid patterns in patients with a genetic form of high cholesterol, which may explain their higher risk of heart disease.

## Contribution

The study reveals a distinct lipidomic signature in FH patients with pathogenic variants, potentially explaining increased cardiovascular risk.

## Key findings

- Lipid classes were elevated in FH patients compared to healthy controls.
- Sphingomyelins distinguished HeFH from FH/V−/USV− patients.
- Lipidomic differences correlate with cardiovascular risk in HeFH patients.

## Abstract

Familial Hypercholesterolemia (FH) is a common genetic disorder characterized by elevated LDL-cholesterol levels and an increased risk of premature cardiovascular disease. While pathogenic variants in LDLR, APOB, and PCSK9 are well-established causes, a substantial proportion of clinically suspected FH cases do not carry either pathogenic variants or rare variants of uncertain significance in these genes (FH/V−/USV−). This study aimed to characterize the metabolome/lipidome of genetically confirmed heterozygous FH (HeFH) patients compared to FH/V−/USV−, seeking to identify specific alterations associated with genetic status and phenotypic variability. Untargeted high-resolution mass spectrometry (UHPLC-Q-Exactive-MS)-based lipidomics and nuclear magnetic resonance-based metabolomics were performed on plasma samples of FH patients (n = 20 HeFH and n = 19 FH/V−/USV−) towards healthy controls (n = 22). PLS-DA analysis revealed group-level separation, suggesting differences in the circulating metabolome/lipidome. As expected, most of identified lipid classes were higher in both FH groups compared to normolipidemic controls. Notably, significant lipids (VIP > 1, p < 0.05) showed potential in distinguishing HeFH and FH/V−/USV− patients, particularly sphingomyelins. These data were confirmed by multivariable regression analysis controlling for age, sex, and lipid-lowering therapy as well as by ROC analysis. The evidence of a distinct lipidome signature in the HeFH subgroup may relate to the increased cardiovascular risk of HeFH patients compared to patients without pathogenic variants.